Development of tests for the diagnosis of Covid-19 – COVIDIAG
In order to address the health crisis around the SARS-CoV-2 infection, there is a growing need and demand for diagnostic tools that are complementary and different from the RT-PCR currently in use. Moreover, in view of the worldwide demand for testing, it is important to have new tools and tests produced entirely in France but accessible to the entire medical and scientific community.
We propose to synthesize different surface proteins of SARS-CoV-2 in recombinant form. These recombinant proteins will allow:
(i) The development of serological tests (ELISA) in order to detect specific antibodies directed against SARS-CoV-2 and determine the seroprevalence against this virus in the coming months.
(ii) Immunization of mice for the production of monoclonal antibodies specifically directed against SARS-CoV-2 as a basis for the development of an immunochromatographic test for the rapid detection of SARS-CoV-2 in respiratory samples.
(iii) The development by a different strategy (competitive testing) of an immunochromatographic test for the rapid detection of SARS-CoV-2 in respiratory samples.
Thanks to our experience in this field, and the complementarity of our teams, we are able to rapidly develop and test these diagnostic tools from the cohort of respiratory and blood samples of positive patients and thus meet a growing medical and public health need.
Monsieur ETIENNE BROCHOT (AGIR Agents infectieux, résistance et chimiothérapie)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
UR UPJV 4294 AGIR Agents infectieux, résistance et chimiothérapie
ISP UMR INRAE 1282 Infectiologie et santé Publique
Help of the ANR 30,000 euros
Beginning and duration of the scientific project: March 2020 - 12 Months